EBOS Group’s $1.1 billion acquisition of Symbion has been voted the Best New Zealand Deal of the Year in the 2013 FinanceAsia Achievement Awards.
The annual FinanceAsia awards recognise excellence in finance across the Asia region and the award summary refers to EBOS Group’s “audacious NZ$1.1 billion acquisition of Australian pharmaceutical firm Symbion – a company twice its size”.
Chapman Tripp advised EBOS on the acquisition. Partner, Alister McDonald, who led the transaction said: “EBOS Group is to be congratulated for making such a bold and transformational move in the current business climate and it thoroughly deserves the recognition that this award brings, along with its award for “Best Growth Strategy” for the Symbion transaction at the recent Deloitte Top 200 Awards.”
“We were delighted to be involved in this ambitious deal.”
Chapman Tripp’s advice to EBOS Group on the acquisition included obtaining Overseas Investment Office and other regulatory and shareholder approvals, and conducting a $239m public capital raising and $140m debt extension and refinancing. In addition to Alister McDonald, the Chapman Tripp team included Chris Dann, Roger Wallis, Cathryn Barber, Joshua Pringle and Callum Harper.